MedTrace Logo

A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

NCT06315491 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-10-06

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.

Conditions

Interventions

DRUG

CBX-12

CBX-12 is an alphalex construct which contains exatecan as the pharmacologically active moiety.

Sponsors & Collaborators

  • Cybrexa Therapeutics

    lead INDUSTRY

Principal Investigators

  • Michael Needle, MD · Cybrexa Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-25
Primary Completion
2025-10-31
Completion
2025-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06315491 on ClinicalTrials.gov